| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Ganodermadiol targets cellular pathways involved in inflammation, oxidative stress, and cell proliferation, consistent with the known bioactivities of Ganoderma triterpenes. As a lanostane-type triterpenoid, it is expected to interact with molecular targets such as NF-κB, STAT3, and other signaling molecules involved in cancer and inflammation. The compound may also modulate enzyme activities including 5-alpha reductase and other targets characteristic of this compound class. Its specific molecular targets require further elucidation through targeted biochemical studies.
|
|---|---|
| ln Vitro |
Ganodermadiol exhibits bioactivities characteristic of Ganoderma triterpenes, including anti-inflammatory, antioxidant, and potential anticancer effects. In vitro studies on related compounds from Ganoderma lucidum have demonstrated cytotoxicity against various cancer cell lines, inhibition of inflammatory mediators, and antioxidant activity. The compound's effects on cell proliferation and survival are likely mediated through modulation of signaling pathways such as NF-κB and STAT3. Further in vitro characterization is needed to establish its specific potency and mechanism of action.
|
| ln Vivo |
In vivo, ganodermadiol is expected to exhibit activities consistent with other Ganoderma triterpenes, including anti-inflammatory, hepatoprotective, and immunomodulatory effects. Ganoderma lucidum extracts containing ganodermadiol and related compounds have shown beneficial effects in animal models of inflammation, liver injury, and cancer. The compound's in vivo efficacy would depend on its bioavailability and distribution following administration. Specific in vivo studies on ganodermadiol are limited in the available literature.
|
| Enzyme Assay |
In vitro enzyme assays for ganodermadiol would typically involve measuring its inhibition of target enzymes such as 5-alpha reductase, β-glucuronidase, or aldose reductase, similar to assays used for related Ganoderma triterpenes. These assays use purified enzyme preparations and appropriate substrates to determine inhibitory potency. The compound's antioxidant activity can be assessed using standard cell-free assays such as DPPH radical scavenging or ABTS assays. Anti-inflammatory activity can be evaluated by measuring inhibition of COX-2 or other inflammatory enzymes.
|
| Cell Assay |
In vitro cell-based assays for ganodermadiol would involve treating cancer cell lines or immune cells with the compound to assess cytotoxicity, anti-inflammatory effects, and modulation of signaling pathways. Cell viability is measured using MTT or similar assays. Apoptosis is quantified by flow cytometry. Inflammatory cytokine production is measured by ELISA. Signaling pathway modulation is assessed by Western blotting for phosphorylated proteins. These assays would establish the compound's cellular activities and mechanisms of action.
|
| Animal Protocol |
In vivo animal experiments for ganodermadiol would be conducted in models of inflammation, liver injury, or cancer, similar to studies on other Ganoderma triterpenes. Mice or rats would be treated with the compound orally or via injection, and efficacy endpoints would include biomarker analysis, histopathology, and functional assessments. Dose-response relationships would be established. Specific in vivo studies on ganodermadiol are limited in the available literature.
|
| ADME/Pharmacokinetics |
Ganodermadiol has a molecular weight and formula characteristic of lanostane-type triterpenoids (approximately C30H50O2). It is a lipophilic compound typical of triterpenes, with limited aqueous solubility. The compound is extracted from Ganoderma lucidum using organic solvents. Its pharmacokinetic properties, including absorption, distribution, metabolism, and elimination, are expected to be similar to other lanostane triterpenoids. Specific pharmacokinetic data has not been extensively reported.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for ganodermadiol is not extensively reported. As a natural compound from Ganoderma lucidum, which has a long history of use in traditional medicine, it is generally considered to have a favorable safety profile. However, comprehensive toxicological studies would be required for therapeutic development. Standard safety precautions should be taken when handling the compound in research settings.
|
| References | |
| Additional Infomation |
Ganoderol B is a tetracyclic triterpenoid compound with the structure lanostane-7,9(11),24-triene, substituted with hydroxyl groups at positions 3 and 27. It has been isolated from various Ganoderma fungi. Ganoderol B possesses hepatoprotective, antiviral, and fungal metabolic effects. It is a 3β-sterol, primary allyl alcohol, and tetracyclic triterpenoid compound derived from the hydrogenation of lanostane. It has been reported that Ganoderol B exists in soybean (Glycine max), Ganoderma pfeifferi, and other organisms with relevant data.
Ganodermadiol is a lanostane-type triterpenoid isolated from Ganoderma lucidum. It belongs to the class of bioactive triterpenes found in this medicinal mushroom that are known for their diverse pharmacological activities including anti-inflammatory, antioxidant, and anticancer effects. Ganodermadiol is one of several bioactive constituents contributing to the therapeutic properties of Ganoderma lucidum. Further research is needed to fully characterize its specific biological activities and mechanisms of action. |
| Molecular Formula |
C30H48O2
|
|---|---|
| Molecular Weight |
440.71
|
| Exact Mass |
440.365
|
| CAS # |
104700-96-1
|
| PubChem CID |
13934286
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
552.7±50.0 °C at 760 mmHg
|
| Flash Point |
226.1±24.7 °C
|
| Vapour Pressure |
0.0±3.4 mmHg at 25°C
|
| Index of Refraction |
1.551
|
| LogP |
8.82
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
32
|
| Complexity |
832
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
C[C@H](CC/C=C(\C)/CO)[C@H]1CC[C@@]2([C@@]1(CC=C3C2=CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)C)C
|
| InChi Key |
AOXXVRDKZLRGTJ-AZIDVCJLSA-N
|
| InChi Code |
InChI=1S/C30H48O2/c1-20(19-31)9-8-10-21(2)22-13-17-30(7)24-11-12-25-27(3,4)26(32)15-16-28(25,5)23(24)14-18-29(22,30)6/h9,11,14,21-22,25-26,31-32H,8,10,12-13,15-19H2,1-7H3/b20-9+/t21-,22-,25+,26+,28-,29-,30+/m1/s1
|
| Chemical Name |
(3S,5R,10S,13R,14R,17R)-17-[(E,2R)-7-hydroxy-6-methylhept-5-en-2-yl]-4,4,10,13,14-pentamethyl-2,3,5,6,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-3-ol
|
| Synonyms |
Ganoderol B; (+)-Ganoderol B; Ganodermadiol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2691 mL | 11.3453 mL | 22.6907 mL | |
| 5 mM | 0.4538 mL | 2.2691 mL | 4.5381 mL | |
| 10 mM | 0.2269 mL | 1.1345 mL | 2.2691 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
